title: Engaging novel cell types, protein targets and efficacy biomarkers in the treatment of diabetic nephropathy.
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Inc., Cardiometabolic Diseases Research Ridgefield, CT, USA.
authors.forename: Ryan M
authors.initials: RM
authors.lastname: Fryer
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Inc., Cardiometabolic Diseases Research Ridgefield, CT, USA.
authors.forename: Carine M
authors.initials: CM
authors.lastname: Boustany-Kari
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Inc., Cardiometabolic Diseases Research Ridgefield, CT, USA.
authors.forename: Scott M
authors.initials: SM
authors.lastname: MacDonnell
keywords: ERK5; MEK5; N-acetyl-seryl-aspartyl-lysyl-proline; PF-03882845; angiopoietin-like protein 4; chronic kidney disease; diabetic nephropathy; mineralocorticoid antagonist